172 related articles for article (PubMed ID: 35486806)
21. Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections.
Abu-Raddad LJ; Chemaitelly H; Ayoub HH; Tang P; Coyle P; Hasan MR; Yassine HM; Benslimane FM; Al-Khatib HA; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Khal A; Al-Thani MH; Bertollini R
Nat Commun; 2022 Jan; 13(1):532. PubMed ID: 35087035
[TBL] [Abstract][Full Text] [Related]
22. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework.
Wang X; Haeussler K; Spellman A; Phillips LE; Ramiller A; Bausch-Jurken MT; Sharma P; Krivelyova A; Vats S; Van de Velde N
Front Immunol; 2023; 14():1204831. PubMed ID: 37771594
[TBL] [Abstract][Full Text] [Related]
24. Pneumonia Frequency and Severity in Patients With Symptomatic COVID-19: Impact of mRNA and Adenovirus Vector Vaccines.
Vicini S; Bellini D; Iannarelli A; Rengo M; Pelle G; Ruggiero S; Fusco M; Ambrogi C; Carbone I
AJR Am J Roentgenol; 2022 Nov; 219(5):752-761. PubMed ID: 35642761
[No Abstract] [Full Text] [Related]
25. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines.
Brunner-Ziegler S; Spath T; Kornek G; König F; Parschalk B; Schnetzinger M; Straßl RP; Savic R; Foit A; Resch H; Thalhammer F
Clin Microbiol Infect; 2022 Apr; 28(4):596-601. PubMed ID: 34915073
[TBL] [Abstract][Full Text] [Related]
26. The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data.
Kshirsagar M; Nasir M; Mukherjee S; Becker N; Dodhia R; Weeks WB; Ferres JL; Richardson B
JMIR Public Health Surveill; 2022 Nov; 8(11):e38898. PubMed ID: 36265135
[TBL] [Abstract][Full Text] [Related]
27. Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States.
Mues KE; Kirk B; Patel DA; Gelman A; Chavers LS; Talarico CA; Esposito DB; Martin D; Mansi J; Chen X; Gatto NM; Van de Velde N
Vaccine; 2022 Nov; 40(47):6730-6739. PubMed ID: 36163093
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021.
Tenforde MW; Patel MM; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Botros M; Lauring AS; Shapiro NI; Halasa N; Chappell JD; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Rhoads JP; Lindsell CJ; Hart KW; Zhu Y; Naioti EA; Adams K; Lewis NM; Surie D; McMorrow ML; Self WH;
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):118-124. PubMed ID: 35085218
[TBL] [Abstract][Full Text] [Related]
29. Incidence and Risk Factors of COVID-19 Vaccine Breakthrough Infections: A Prospective Cohort Study in Belgium.
Stouten V; Hubin P; Haarhuis F; van Loenhout JAF; Billuart M; Brondeel R; Braeye T; Van Oyen H; Wyndham-Thomas C; Catteau L
Viruses; 2022 Apr; 14(4):. PubMed ID: 35458532
[TBL] [Abstract][Full Text] [Related]
30. Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy).
Basso P; Negro C; Cegolon L; Larese Filon F
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215930
[No Abstract] [Full Text] [Related]
31. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women.
Goldshtein I; Nevo D; Steinberg DM; Rotem RS; Gorfine M; Chodick G; Segal Y
JAMA; 2021 Aug; 326(8):728-735. PubMed ID: 34251417
[TBL] [Abstract][Full Text] [Related]
32. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden.
Nordström P; Ballin M; Nordström A
Lancet; 2022 Feb; 399(10327):814-823. PubMed ID: 35131043
[TBL] [Abstract][Full Text] [Related]
33. Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination.
Beatty AL; Peyser ND; Butcher XE; Cocohoba JM; Lin F; Olgin JE; Pletcher MJ; Marcus GM
JAMA Netw Open; 2021 Dec; 4(12):e2140364. PubMed ID: 34935921
[TBL] [Abstract][Full Text] [Related]
34. Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 2021.
Wang W; Kaelber DC; Xu R; Berger NA
JAMA Oncol; 2022 Jul; 8(7):1027-1034. PubMed ID: 35394485
[TBL] [Abstract][Full Text] [Related]
35. Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative.
Song Q; Bates B; Shao YR; Hsu FC; Liu F; Madhira V; Mitra AK; Bergquist T; Kavuluru R; Li X; Sharafeldin N; Su J; Topaloglu U
J Clin Oncol; 2022 May; 40(13):1414-1427. PubMed ID: 35286152
[TBL] [Abstract][Full Text] [Related]
36. Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans.
Dickerman BA; Gerlovin H; Madenci AL; Kurgansky KE; Ferolito BR; Figueroa Muñiz MJ; Gagnon DR; Gaziano JM; Cho K; Casas JP; Hernán MA
N Engl J Med; 2022 Jan; 386(2):105-115. PubMed ID: 34942066
[TBL] [Abstract][Full Text] [Related]
37. Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study.
Patel NJ; Wang X; Fu X; Kawano Y; Cook C; Vanni KMM; Qian G; Banasiak E; Kowalski E; Zhang Y; Sparks JA; Wallace ZS
Semin Arthritis Rheum; 2023 Feb; 58():152108. PubMed ID: 36347211
[TBL] [Abstract][Full Text] [Related]
38. Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis.
John BV; Deng Y; Scheinberg A; Mahmud N; Taddei TH; Kaplan D; Labrada M; Baracco G; Dahman B
JAMA Intern Med; 2021 Oct; 181(10):1306-1314. PubMed ID: 34254978
[TBL] [Abstract][Full Text] [Related]
39. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375
[TBL] [Abstract][Full Text] [Related]
40. Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine.
Islam N; Sheils NE; Jarvis MS; Cohen K
Nat Commun; 2022 May; 13(1):2377. PubMed ID: 35501319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
